Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Chuang

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Cancer Gene Therapy|April 20, 2013
Expression of β-glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugsC-M Cheng, F M Chen, Y-L Lu, et al.
Scientific Reports|April 11, 2014
The effect of thermal reduction on the photoluminescence and electronic structures of graphene oxidesC-H Chuang, Y-F Wang, Y-C Shao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2024
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose explorationJ Rodon, H Prenen, A Sacher, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Cancer Gene Therapy|April 20, 2013
Expression of β-glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugsC-M Cheng, F M Chen, Y-L Lu, et al.
Scientific Reports|April 11, 2014
The effect of thermal reduction on the photoluminescence and electronic structures of graphene oxidesC-H Chuang, Y-F Wang, Y-C Shao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2024
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose explorationJ Rodon, H Prenen, A Sacher, et al.
Pageof 7